Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma
Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is an uncommon disorder with germline-inactivating mutations in the fumarate hydratase ( FH) gene. The kidney cancers that develop in patients with HLRCC are often unilateral and solitary, with a potentially aggressive clinical course; morphologic identification of suspicious cases is of the utmost importance.
In clinical trials evaluating cancer interventions, there was no significant association between progression-free survival and health-related quality of life, according to research published in JAMA Internal Medicine.
What Makes the Nobel-Winning Breakthroughs in Immunotherapy So Revolutionary Read more: https://www.smithsonianmag.com/science-nature/nobel-winning-breakthroughs-in-immunotherapy-revolutionary-1809704
This week, the 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo for their breakthrough discoveries in immunotherapy. This article by Smithsonian Magazine explains the importance of this approach in treating cancer.
The dismal prognosis for patients with metastatic renal cell carcinoma (mRCC) has fueled an earnest quest for more effective treatments, culminating in a better understanding of the disease and regulatory approval of several new drugs and therapeutic combinations.
The use of robotic tumor enucleation conferred favorable long-term surgical margins and local recurrence rates in patients with sporadic renal cell carcinoma (RCC), according to the results of a single-center Italian study.
Smoking, obesity, hypertension and chronic kidney disease are risk factors for kidney cancer.
We invite you to become a member of PracticeUpdate and the Renal Cell Carcinoma Center of Excellence, an expert-curated resource that’s dedicated to practicing physicians. The Renal Cell Carcinoma Center of Excellence provides physicians with the most up to date information on patient care.
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
Being overweight or obese as an adult increases the risk of 13 different types of cancer including breast, bowel and kidney cancer, but only around one in seven people in the UK are aware of the link.
Susan from Alberta, Canada, was diagnosed with stage 1 kidney cancer at age 25. After receiving a radical right nephrectomy, she has remained cancer-free for 12 years. Below, Susan shares her best advice for those going through a similar situation: 1.) Ask questions and record everything so you can remember what the doctor says. It will also serve as a journal for you down the road. 2.) Be kind to yourself. There will be bad days, hard days, but there will be many good days as well so enjoy those when they come. 3.) Let your close loved ones know when you are having a bad day, don’t keep your feelings to yourself. In my situation, I had to be the “strong” one for my mom and sister but at night, in secret, I fell apart and that was an unnecessary burden on me. I didn’t know how strong I was until being strong was the only choice I had. If you'd like to share your story with us, email firstname.lastname@example.org.
|NeonCRM by Neon One|